5.18 USD
0 (0%)
5.18 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to ORGO. ORGO was compared to 530 industry peers in the Biotechnology industry. ORGO has an average financial health and profitability rating. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ORGO had positive earnings in the past year.
In the past year ORGO has reported a negative cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
Each year in the past 5 years ORGO had a positive operating cash flow.
1.2 Ratios
ORGO has a Return On Assets of -2.63%. This is amongst the best in the industry. ORGO outperforms 87.55% of its industry peers.
The Return On Equity of ORGO (-3.47%) is better than 89.25% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.16%, ORGO belongs to the top of the industry, outperforming 88.87% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROIC | 0.16% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
ORGO has a Operating Margin of 0.18%. This is amongst the best in the industry. ORGO outperforms 88.87% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
The Gross Margin of ORGO (74.49%) is better than 83.40% of its industry peers.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
ORGO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.47 indicates that ORGO is not in any danger for bankruptcy at the moment.
ORGO has a Altman-Z score of 4.47. This is in the better half of the industry: ORGO outperforms 71.51% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ORGO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, ORGO perfoms like the industry average, outperforming 47.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.47 |
ROIC/WACC0.02
WACC8.9%
2.3 Liquidity
A Current Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
The Current ratio of ORGO (3.32) is worse than 60.00% of its industry peers.
ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.88, ORGO is not doing good in the industry: 63.58% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
The earnings per share for ORGO have decreased strongly by -90.91% in the last year.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
The Revenue has been growing slightly by 2.24% in the past year.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 29.27% on average per year.
The Revenue is expected to grow by 8.70% on average over the next years. This is quite good.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 518.00 indicates a quite expensive valuation of ORGO.
88.87% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of ORGO to the average of the S&P500 Index (26.51), we can say ORGO is valued expensively.
The Price/Forward Earnings ratio is 35.02, which means the current valuation is very expensive for ORGO.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 91.89% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.13, ORGO is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 518 | ||
| Fwd PE | 35.02 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 92.45% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 31.35 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 29.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
5. Dividend
5.1 Amount
ORGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.18
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners54.82%
Inst Owner Change-1.32%
Ins Owners31.5%
Ins Owner Change-0.43%
Market Cap657.39M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (67.37%)
Short Float %16.7%
Short Ratio5.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)6.25%
PT rev (3m)6.25%
EPS NQ rev (1m)23.53%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)216.67%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)3.66%
Revenue NQ rev (3m)6.21%
Revenue NY rev (1m)5.49%
Revenue NY rev (3m)5.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 518 | ||
| Fwd PE | 35.02 | ||
| P/S | 1.41 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.7 | ||
| P/tB | 1.89 | ||
| EV/EBITDA | 31.35 |
EPS(TTM)0.01
EY0.19%
EPS(NY)0.15
Fwd EY2.86%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROCE | 0.2% | ||
| ROIC | 0.16% | ||
| ROICexc | 0.19% | ||
| ROICexgc | 0.21% | ||
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 70.73% | ||
| Cap/Sales | 2.76% | ||
| Interest Coverage | 0.99 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | 4.47 |
F-Score2
WACC8.9%
ROIC/WACC0.02
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 5 / 10 to ORGO.
Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
What is the profitability of ORGO stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.
What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?
The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.